EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Results of the ACCOuNT Trial: A Multi‐Institutional Prospective Pharmacogenomics Implementation Trial for African American Inpatients

Zhong Huang iD, Kevin J O'Leary, Edith A Nutescu, Matthew Jack iD, Thomas Chen, Gregory W Ruhnke, James C Lee iD, David George, Larry K House iD, Randall Knoebel iD, Luke V Rasmussen iD, Seth Hartman und 6 weitere

Clinical Pharmacology & Therapeutics · 2026

DOI: 10.1002/cpt.70024 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Zhong Huang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Pritzker School of Medicine, The University of Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Black or African American, Decision Support Systems, Clinical, Pharmacogenetics. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIMHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacogenomics implementation efforts have increased over the last decade, but no published prospective pharmacogenomics trials have formally evaluated utility in underrepresented populations. We present final results from the ACCOuNT trial, a multi‐institutional prospective study [NCT03225820] in which African American inpatients were genotyped and pharmacogenomic results made available via an integrated, scalable pharmacogenomics clinical decision support (PGx CDS) system to guide prescribing. We hypothesized that PGx CDS utilization would improve genomically concordant prescribing during inpatient admissions. We recruited 531 patients, of which 187 were readmitted (60.4% female, median age = 55 [range: 19–88], median readmissions/patient = 2 [range: 1–17]), resulting in 518 evaluable admissions during which the effect of available pharmacogenomic results was measured. In 50% of admissions, care teams utilized PGx CDS. 12% of inpatient prescriptions had pharmacogenomic annotations, with only 3.6% pharmacogenomically associated with increased caution (“discordant”); no PGx high‐risk medications were prescribed. PGx CDS use by provider teams did not decrease genomically discordant prescribing (3.9% vs. 3.3% without PGx CDS use, P = 0.53). Nevertheless, inpatient care teams repeatedly consulted PGx CDS ostensibly to affirm genomically concordant prescriptions, as 48% of all admissions and 91% of discharges included pharmacogenomically annotated medications, mostly genomically concordant. Notably, timing of PGx CDS utilization correlated tightly with prescribing timing (correlation coefficient = 0.84, P < 0.05). In the first results of a multi‐institutional, prospective pharmacogenomics trial focused on underrepresented patients, we found the relevance of currently actionable pharmacogenomics information for guiding inpatient prescribing to be modest; but observed frequent use of concordant pharmacogenomics to affirm prescribing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Black or African AmericanDecision Support Systems, ClinicalPharmacogeneticsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedYoung AdultInpatientsPatient ReadmissionProspective Studies

Autor:innen und Institutionen

  • Pritzker School of Medicine, The University of Chicago, Chicago, Illinois, USA.
  • Division of Hospital Medicine, Department of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Department of Pharmacy Practice, University of Illinois Chicago, Chicago, Illinois, USA.
  • Center for Personalized Therapeutics, The University of Chicago, Chicago, Illinois, USA.
  • Section of Hospital Medicine, Department of Medicine, The University of Chicago, Chicago, Illinois, USA.
  • Department of Pathology, The University of Chicago, Chicago, Illinois, USA.

ORCID-Profile: Zhong Huang, Matthew Jack, James C Lee, Larry K House, Randall Knoebel, Luke V Rasmussen, Kiang-Teck J Yeo, Minoli A Perera, Mark J Ratain, Peter H O'Donnell

Förderung

  • NIMHD NIH HHS

Zitieren

APA

Huang, Z., O'Leary, K. J., Nutescu, E. A., Jack, M., Chen, T., Ruhnke, G. W., Lee, J. C., George, D., House, L. K., Knoebel, R., Rasmussen, L. V., Hartman, S., Choksi, A., Yeo, K. J., Perera, M. A., Ratain, M. J., Meltzer, D. O., & O'Donnell, P. H. (2026). Results of the ACCOuNT Trial: A Multi‐Institutional Prospective Pharmacogenomics Implementation Trial for African American Inpatients. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70024

Vancouver

Huang Z, O'Leary KJ, Nutescu EA, Jack M, Chen T, Ruhnke GW, et al. Results of the ACCOuNT Trial: A Multi‐Institutional Prospective Pharmacogenomics Implementation Trial for African American Inpatients. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70024

BibTeX
@article{Huang2026,
  author = {Huang, Zhong and O'Leary, Kevin J and Nutescu, Edith A and Jack, Matthew and Chen, Thomas and Ruhnke, Gregory W and Lee, James C and George, David and House, Larry K and Knoebel, Randall and Rasmussen, Luke V and Hartman, Seth and Choksi, Anish and Yeo, Kiang-Teck J and Perera, Minoli A and Ratain, Mark J and Meltzer, David O and O'Donnell, Peter H},
  title = {Results of the ACCOuNT Trial: A Multi‐Institutional Prospective Pharmacogenomics Implementation Trial for African American Inpatients},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70024}
}
Kostenlos starten →